PTSD

Ibogaine By David Dardashti Offers Free Online Support for Post-Treatment Care

Retrieved on: 
Tuesday, February 6, 2024
DSM-IV codes, PTSD, Ibogaine, Opioid, Depression, Life, Senior counsel

To help those who have already completed treatment, Ibogaine By David Dardashti is now offering free online support for those in need.

Key Points: 
  • To help those who have already completed treatment, Ibogaine By David Dardashti is now offering free online support for those in need.
  • “At Ibogaine By David Dardashti, we strive to provide the highest level of care and nurturing to those who are fighting addiction or mental health issues,” said Dr. David Dardashti.
  • That’s why we’ve implemented this free online support program.” The free online support program will provide clients with counseling and support in the months following treatment.
  • Ibogaine By David Dardashti encourages anyone who has recently completed treatment to take advantage of their free online support program.

Talkiatry Named to the New York Digital Health 100 by Digital Health New York (DHNY)

Retrieved on: 
Tuesday, February 6, 2024
PTSD, Cigna, Anxiety, Digital health, Child, Patient, Digital, ADHD, OCD, Depression, Insurance, Medicare, Bipolar disorder, Cryptocurrency

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatric care, today announced that it has been named to the 2024 New York Digital Health 100 (DH100), a recognition that highlights the most exciting and innovative startups in New York. Digital Health New York (DHNY) publishes the annual list in conjunction with the New York Healthcare Innovation Report which takes an in-depth look at the investment trends, opportunities and challenges in the digital health sector.

Key Points: 
  • NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Talkiatry , a leading provider of high-quality, in-network psychiatric care, today announced that it has been named to the 2024 New York Digital Health 100 (DH100), a recognition that highlights the most exciting and innovative startups in New York.
  • Digital Health New York (DHNY) publishes the annual list in conjunction with the New York Healthcare Innovation Report which takes an in-depth look at the investment trends, opportunities and challenges in the digital health sector.
  • "The digital health landscape in New York City is dynamic, and it's an honor to be recognized amongst our peers on the New York Digital Health 100 list for the second year in a row," said Robert Krayn, co-founder and CEO, Talkiatry.
  • "2024 marks the fifth year of the New York Digital Health 100 and in that time, the digital health ecosystem in New York has significantly grown and evolved," said Bunny Ellerin, co-founder and CEO, DHNY.

Relief Mental Health Expands Access to Treatment: IV Ketamine Now Available in Additional Chicagoland Clinics

Retrieved on: 
Tuesday, February 6, 2024
Other Consumer, Mental Health, Women, Seniors, LGBTQ+, Men, Other Health, Pharmaceutical, Consumer, Health, PTSD, Anxiety, Mental health, Patient, Transcranial magnetic stimulation, Patient safety, Safety, DSM-IV codes, FDA, OCD, Ketamine, TMS, Depression, Brain, Quality of life, Risk, Learning, Tic disorder, Lifting, Nursing

Relief Mental Health , a leading provider of innovative mental health treatments, announced today the expansion of IV ketamine to multiple clinics across the Chicagoland area, including Chicago West Loop, Northbrook, Oak Brook , Orland Park and St. Charles.

Key Points: 
  • Relief Mental Health , a leading provider of innovative mental health treatments, announced today the expansion of IV ketamine to multiple clinics across the Chicagoland area, including Chicago West Loop, Northbrook, Oak Brook , Orland Park and St. Charles.
  • "We are pleased to extend our IV ketamine services to additional clinics throughout Chicagoland," said Susan Mueller, CEO, Relief Mental Health.
  • The decision to expand IV ketamine treatment services reflects Relief’s commitment to providing comprehensive, personalized care to patients in need.
  • Relief Mental Health remains steadfast in its dedication to promoting mental wellness and empowering individuals to reclaim their lives from the grips of mental illness.

GrayMatters Health Announces Pioneering Study Highlighting Safety and Efficacy of Self-Neuromodulation for PTSD

Retrieved on: 
Tuesday, February 6, 2024
PTSD, Checklist, Research, Magnetic resonance, Psychiatry, Patient, Safety, FDA, GMH, NYU Langone Health, EFP, Computer simulation, Patient Health Questionnaire, Entrepreneurship, Psychotherapy, Mental health, DSM-5, Journal, EEG, Health, Woman

HAIFA, Israel and NEW YORK, Feb. 6, 2024 /PRNewswire/ -- GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental health care, announces the publication of a peer-reviewed article in the Journal of Psychiatry Research demonstrating the safety and efficacy of its FDA-cleared Prism for PTSD device. The prospective, single arm, multi-site, open label trial evaluated men, women, and treatment-resistant combat veterans with chronic post-traumatic stress disorder (PTSD).

Key Points: 
  • The prospective, single arm, multi-site, open label trial evaluated men, women, and treatment-resistant combat veterans with chronic post-traumatic stress disorder (PTSD).
  • Prism for PTSD is the first self-neuromodulation device to receive FDA clearance as a prescribed adjunct to standard-of-care for PTSD.
  • The treatment, now available in select clinics in the United States, digitizes brain activity associated with PTSD to scientifically help patients gain control of their PTSD symptoms.
  • Prism for PTSD uses a computer simulation and EEG headset to create a novel, immersive environment for training individuals to self-modulate an amygdala-based biomarker associated with PTSD.

Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners

Retrieved on: 
Tuesday, February 6, 2024
PTSD, Chase, Research, FRA, Quality assurance, Safety, Psilocybin, PST, FDA, MDMA, Food, Trust, Health, Lycus, GMP, NDA, Pharmacist, Pharmaceutical industry

VANCOUVER, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is announcing an informative webinar titled “Know Your Drug Candidate: Safeguarding Quality in Psychedelic Therapy.” This event, scheduled for Tuesday, February 13, 2024, at 2:00 p.m. Pacific Standard Time (PST), is a crucial opportunity for clinicians, scientists, researchers, therapists, pharmacists, and regulators involved or interested in the GMP manufacturing of psychedelic drug substances.

Key Points: 
  • Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.
  • Optimi experts will address critical inquiries which still exist on the definition of validated GMP psilocybin, MDMA, and other psychedelic substances.
  • Optimi is the only end-to-end, publicly listed psychedelics company currently offering its drug candidates at scale to address accessibility through lower costs.
  • Both individuals, considered experts in their respective fields, currently lead the Company's cutting-edge science and quality assurance divisions.

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Retrieved on: 
Thursday, February 1, 2024
Traffic barrier, PTSD, Multiple sclerosis, Inflammation, Fibromyalgia, Chronic pain, Research, Plasma protein binding, Therapy, SILO, Neurology, IND, New Drug Application, UMB, Central nervous system, FDA, Columbia University, Ketamine, GLP, Food, Mental health, CNS, Social media, Post-traumatic stress disorder, Administration, University, Pharmaceutical industry

SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced updates for its strategic 2024 focus for its clinical pipeline. The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.

Key Points: 
  • The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.
  • A dose-ranging non GLP study of SPC-15 is in progress, with a final validation report expected in the first half of 2024.
  • As a self-administered treatment, SP-26 holds the potential to be the first at-home ketamine treatment approved for chronic pain management.
  • Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.

Clarion Clinics Open for Psychedelic-Assisted Treatments

Retrieved on: 
Thursday, February 1, 2024
PTSD, Post-traumatic stress disorder, Clarion, TGA, Prohibition of drugs, Therapeutic Goods Administration, Clinical trial, Environment, Patient, Safety, Depression, Psilocybin, TRD, MDMA, Authorization, Psychotherapy, Schedule, Pharmaceutical industry

MELBOURNE, Australia and NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc (Nasdaq: IXHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that Clarion Clinic’s co-Founder and Head of Psychiatry, Professor Suresh Sundram, has received Authorised Prescriber approval from the Therapeutic Goods Administration (TGA) to prescribe MDMA in the treatment of Post-traumatic Stress Disorder (PTSD) and psilocybin for Treatment-resistant Depression (TRD) at its first built-for-purpose clinic based in Melbourne, Australia, a city of approximately 5.2M people.

Key Points: 
  • Clarion Clinics’ built-for-purpose clinic in Melbourne is now open for treatment, and will begin screening patients immediately.
  • Clarion Clinics is a collaboration between Australia’s leading psychedelic-assisted therapy professionals and scientists, and Incannex.
  • Clarion Clinics, Abbottsford, will be the first dedicated psychedelic-assisted therapy clinic in Australia.
  • Clarion is at the leading edge of mental healthcare, has the right protocols, and an experienced team ready to help people through these challenging conditions,” Peter Widdows, Incannex Director responsible for Clarion Clinics, said.

$20,000 Awarded to Visionary Creators Transforming Representation in the Disability Community

Retrieved on: 
Thursday, February 1, 2024
PTSD, Disability, Life, Senior, Getty, Photography, Domestic violence, Verizon Communications, Disability studies, Beauty, Trauma, Getty Images, Immersion, Creative, Creativity, Empowerment, Sport, Portrait, Medical imaging

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, together with Verizon, have today announced the recipients of a $20,000 creative grant aimed at highlighting the diversity, strength, and beauty of the disability community through the lens of joy and empowerment.

Key Points: 
  • This lack of representation, especially in significant life moments, underlines the urgency for authentic portrayals that resonate with the diverse realities of the disability community.
  • "Stereotypes surrounding the physical beauty and capabilities of the disability community impact the way they are perceived at every level," said Dr. Rebecca Swift, Senior VP of Creative at Getty Images.
  • "Verizon proudly collaborates with Getty Images on the Disability Collection, celebrating positive depictions of disability in everyday life.
  • Shimoda believes in the power of art to raise awareness about critical issues and create a sense of community.

PharmAla releases Profitable Q1 Interim Financial Statement and Business Update

Retrieved on: 
Wednesday, January 31, 2024
PTSD, Prohibition of drugs, Research, History, Substance, CDSL, MDXX, Patient, FDA, Authorization, OTC, MDMA, Health Canada, IP, Post-traumatic stress disorder, Bank statement, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to present its Q1 Interim Financial Statement for the period ending November 30, 2023.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to present its Q1 Interim Financial Statement for the period ending November 30, 2023.
  • PharmAla showed a quarterly profit for the first time in its history, validating its low-overhead manufacturing business model.
  • PharmAla believes that this is the first quarterly profit for any publicly-traded psychedelics company.
  • PharmAla will be hosting an investor webinar on Friday the 2nd to further elaborate on its financial report as well as discuss their recent achievement of obtaining a Controlled Drugs & Substances Dealer’s License (CDSL) from Health Canada.

Unchained Wellness Clinic Paves the Way for Revolutionary Mental Health Care in Gilbert, Arizona

Retrieved on: 
Thursday, February 1, 2024
Theta, PTSD, Anxiety, Multimedia, Inflammation, Transcranial magnetic stimulation, Medication, Life, Sobriety, Immune system, Habit, FDA, Wellness, ADHD, OCD, Law enforcement, Unchained, TMS, Depression, Social media, Hyperbaric medicine, Brain, Privacy, Hope, ADD, Naturopathy, Major depressive disorder, Veteran, Nursing

GILBERT, Ariz., Feb. 1, 2024 /PRNewswire-PRWeb/ -- Unchained Wellness Clinic, a beacon of hope for individuals grappling with mental health challenges, proudly announces its grand opening scheduled for February 2024. Situated in Gilbert, Arizona, this innovative wellness center takes a groundbreaking approach to treat conditions such as depression, anxiety, OCD, PTSD, ADD, ADHD, and addictions without solely relying on medications. Unchained Wellness specializes in identifying the root causes of behavioral health issues and offers a diverse range of services, providing comprehensive care through traditional medications, integrative health, and cutting-edge modalities.

Key Points: 
  • GILBERT, Ariz., Feb. 1, 2024 /PRNewswire-PRWeb/ -- Unchained Wellness Clinic, a beacon of hope for individuals grappling with mental health challenges, proudly announces its grand opening scheduled for February 2024.
  • Unchained Wellness specializes in identifying the root causes of behavioral health issues and offers a diverse range of services, providing comprehensive care through traditional medications, integrative health, and cutting-edge modalities.
  • Unchained wellness gave me a huge jump forward in the healing process that I have never gotten any other way."
  • Unchained Wellness strategically targets towns in Arizona, with a primary focus on Gilbert, Mesa, Chandler, Scottsdale, Tempe, and Queen Creek.